SCHEMBL4283843

SCHEMBL4283843

O=C(O)Cc1cc([N+](=O)[O-])c(F)cc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.49
ATM Q13315 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
LMNA P02545 3/20 0.38
MAPT P10636 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
AKR1B1 P15121 1/20 0.38
HIF1A Q16665 1/20 0.38
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
PKM P14618 1/20 0.36
RAB9A P51151 1/20 0.36
RECQL P46063 1/20 0.36
VCAM1 P19320 1/20 0.36
ESPL1 Q14674 1/20 0.36
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15577420 0.94 CYP1A2 (0.49) CYP1A2ATMTDP1MEN1KMT2A
SCHEMBL15270177 0.86 MEN1 (0.38) CYP1A2ATMTDP1MEN1KMT2A
SCHEMBL4283725 0.85 CYP1A2 (0.53) CYP1A2ATMTDP1MEN1KMT2A
SCHEMBL17009732 0.85 CYP1A2 (0.53) CYP1A2ATMTDP1MEN1KMT2A
SCHEMBL17375033 0.84 CYP1A2 (0.51) CYP1A2ATMTDP1MEN1KMT2A
SCHEMBL2778997 0.82 CYP1A2 (0.57) CYP1A2ATMTDP1MEN1KMT2A
SCHEMBL9565704 0.82 CYP1A2 (0.57) CYP1A2ATMTDP1MEN1KMT2A
SCHEMBL2728932 0.82 CYP1A2 (0.53) CYP1A2ATMTDP1MEN1KMT2A
SCHEMBL4276693 0.81 CYP1A2 (0.49) CYP1A2ATMTDP1MEN1KMT2A
SCHEMBL15577394 0.81 CYP1A2 (0.53) CYP1A2ATMTDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE48731-E1 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2021-09-14 US disclosed
EP-3722296-A2 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC (US) 2020-10-14 EP disclosed
EP-3366293-B1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS LLC (US) 2020-03-11 EP disclosed
EP-3366293-A1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC (US) 2018-08-29 EP disclosed
EP-2858646-B1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS LLC (US) 2017-12-20 EP disclosed
US-9334267-B2 RAF inhibitor compounds DECIPHERA PHARMACEUTICALS, LLC (US) 2016-05-10 US disclosed
US-9334267-B2 RAF inhibitor compounds DECIPHERA PHARMACEUTICALS, LLC (US) 2016-05-10 US disclosed
US-9334267-B2 RAF inhibitor compounds DECIPHERA PHARMACEUTICALS, LLC (US) 2016-05-10 US disclosed
US-20150320759-A1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC 2015-11-12 US disclosed
US-20150119392-A1 RAF INHIBITOR COMPOUNDS DECIPHERA PHARMACEUTICALS, LLC 2015-04-30 US disclosed
US-8940756-B2 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC 2015-01-27 US disclosed
US-20140088075-A1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, INC. (US) 2014-03-27 US disclosed
WO-2013184119-A1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES FLYNN DANIEL L (US) 2013-12-12 WO disclosed
WO-2013134252-A1 2-AMINO, 6 - PHENYL SUBSTITUTED PYRIDO [2, 3 - D] PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2013-09-12 WO disclosed
US-8461179-B1 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2013-06-11 US disclosed
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150320759-A1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES NME1, DCK, NME2 CYP1A2 4556/4885ATM 647/4885TDP1 582/4885
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 CYP1A2 3849/4885ATM 276/4885TDP1 579/4885
US-20140088075-A1 DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES NME1, DCK, NME2 CYP1A2 4556/4885ATM 647/4885TDP1 582/4885
US-20150119392-A1 RAF INHIBITOR COMPOUNDS BRAF, RAF1, NRAS CYP1A2 3423/4885ATM 1028/4885TDP1 2632/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 CYP1A2 3849/4885ATM 276/4885TDP1 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.